Key Dates
May or June, 2022
Date
March, 2022
Abstract Submission Deadline
May or June, 2022
Online Registration Deadline
May or June, 2022
On-site Registration Dates

Registration/注册

郑文富

报告题目:

基于微流控芯片的药物筛选

报告人:

郑文富

所在单位:

国家纳米科学中心

个人简介:

郑文富,国家纳米科学中心研究员。以微流控芯片技术结合纳米材料开展生物医学研究。主要研究方向有(1)微流控及纳米技术在药物递送、药物筛选等方面的应用探索;(2)基于微流控及纳米技术的重大疾病的发病机理、诊断和治疗研究。目前已经发表 SCI 论文 80 余篇,其中影响因子在 10 以上的 23 篇,论文总被引用2500余次。



摘要:


The development of drug candidates or drug combinations for treating challenging diseases such as cancers and neurodegeneration diseases is becoming increasingly urgent. However, the low efficiency of conventional drug screening platforms is a bottleneck limiting the drug evaluation process. We developed series of microfluidics-based platforms for screening drugs with high-throughput and high-accuracy. We developed a micropatterned coculture-based high-content (μCHC) platform by integrating a micropatterned coculture chip with a high-content analysis (HCA) system, for studying the neuron−cancer cell interactions and drug screening (simultaneously detecting 96 kinds of post-drug-treated conditions). The results demonstrate that the μCHC system is a facile platform for screening drug candidates or drug combinations for clinical cancer therapy with high efficiency and fidelity. We also combined a concentration gradient generator (CGG) with a single-cell trapper array (SCA) on microfluidics to evaluate the concentration-dependent bioeffects of various drug candidates. The precise control of the spatiotemporal generation of drug gradients on the CGG and the single-cell-level monitoring of the cell behaviors on the SCA by a high-content system in real time, render the CGG-SCA system a highly precise platform, which can exclude the average effect of cell population and reflect the response of individual cells to the gradient concentrations accurately. The CGG-SCA system provides an automated platform for high-throughput screening of nano medicines with high precision and low sample consumption.